title: Computed tomography-guided transarterial chemoembolization as the initial therapy for hepatocellular carcinoma: experience of 75 cases in a single institute.
abstract: We present the survival rates of 75 nonruptured hepatocellular carcinoma cases initially treated with computed tomography-guided transarterial chemoembolization in a single institute. The 1-, 3-, and 5-year survival rates were 93.9%, 74.7%, and 47.4% in 50 Child's A cases; 75.0%, 43.6%, and 6.8% in 20 Child's B cases; and 60.0%, 40.0%, 0.0% in 5 Child's C cases, respectively. The 1-, 3-, and 5-year survival rates of the 38 estimated resectable hepatocellular carcinoma cases (Child's A, tumors limited in a single lobe) were 94.7%, 82.0%, and 44.6%, respectively. The 1-, 3-, and 5-year survival rates of the 41 cases with estimated indication for percutaneous ethanol injection therapy (tumors less than 3 cm in diameter and three or fewer in number) were 96.8%, 84.6%, and 55.5% in 31 Child's A cases; and 90.0%, 46.7%, and 0% in 10 Child's B cases, respectively. In conclusion, computed tomography-guided transarterial chemoembolization is an excellent primary therapy for hepatocellular carcinoma.
authors.affiliation: Department of Radiology, Tokyo Metropolitan Matsuzawa Hospital, Tokyo, Japan.
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Okada
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Ina
authors.forename: Kazunori
authors.initials: K
authors.lastname: Kubota
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Himeno
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Wakita
authors.forename: Isamu
authors.initials: I
authors.lastname: Ohashi
authors.forename: Naoya
authors.initials: N
authors.lastname: Gomi
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Yoshida
authors.forename: Sunao
authors.initials: S
authors.lastname: Mae
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Irie
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D008099:Liver / Q000000981:diagnostic imaging; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016019:Survival Analysis; D015996:Survival Rate; D014057:Tomography, X-Ray Computed / Q000379:methods*; D016896:Treatment Outcome; D014463:Ultrasonography